0001903596-26-000182
SEC filingALR Technologies reported $25.5K in revenue for FY2025 — a one-time recognition of prior-year GluCurve Pet CGM sales — while generating no revenue during the fiscal year itself, confirming absence of commercial operations amid deepening liquidity stress and auditor-confirmed substantial doubt about its ability to continue as a going concern.
The $25,536 in revenue reported for FY2025 does not reflect current-period sales activity. As stated directly in Item 1 — Business: 'We generated $Nil in revenue during the year ended December 31, 2025.' This amount represents a belated recognition of GluCurve Pet CGM sales originally delivered in prior periods, adjusted under revised accounting application (F-12). No distributor agreements, channel partnerships, or recurring customer contracts are disclosed. The absence of active revenue generation confirms the company remains pre-commercial — a status reinforced by management’s acknowledgment that increased salaries and consulting fees relate solely to personnel supporting the GluCurve Pet CGM product, not scaled operations.
Gross profit increased to $3,440 (from $1,191), yet gross margin remained low at 13.5%. This reflects cost pressures tied to development-stage execution: management notes 'an increase in salaries, payroll expenses and consulting fees paid to personnel related to our GluCurve Pet CGM product,' offset only partially by reductions in travel, market research, and shareholder communications. There is no indication of manufacturing scale, pricing power, or cost efficiencies — only incremental investment against zero revenue realization.
Net loss of $22,057,792 (vs $15,877,514) and diluted EPS of -$0.04 (vs -$0.03) stem from structural deficits, not transitory items. Per Item 1, 'All warrants issued related to our debts have been recorded at their fair value using the Black-Scholes Option Pricing Model and are expensed over the agreed upon term.' Critically, the auditor’s assessment is unambiguous: 'Our recurring losses, anticipated future losses, negative cash flow, need for additional capital and the uncertainties surrounding our ability to raise such funding, raises substantial doubt about our ability to continue as a going concern.' This is not hypothetical — it is a condition affirmed in the financial statements.
Operational fragility is embedded in the supply chain. The filing states CMTSZ has capacity to supply CGM Systems (Exhibit C), yet also warns: 'We have encountered and may continue to encounter difficulties in securing supply of CGM or BGM, including problems involving supplier production capacity and yields, quality control and assurance, component supply, and shortages of qualified personnel.' With no alternative suppliers identified and no evidence of inventory build or order backlog, execution risk remains acute.
As commercialization advances, governance expectations intensify. Management commits that 'our CEO will report to the Board on the risks from cybersecurity incidents on its business strategy, results of operations and financial position.' This signals heightened exposure — not just to data integrity, but to product reliability, regulatory compliance, and customer trust — all without corresponding evidence of revenue, cash generation, or capital stability.